Corvus Pharmaceuticals (CRVS) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[4], including 1 Phase 3[1], 1 Phase 2[2], 1 Phase 1[3].
Trial NCT06561048[5] evaluates Soquelitinib in Peripheral T-Cell Lymphoma, Not Otherwise Specified with a target enrollment of 150 participants.
No Form 4 insider filings for CRVS were recorded at the SEC in the past 30 days[6].